JRF 401
Alternative Names: JRF-401Latest Information Update: 22 Jun 2023
At a glance
- Originator Chengdu Jinrui Foundation Biotech
- Class Antipsoriatics; Antirheumatics
- Mechanism of Action RIPK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Psoriasis; Rheumatoid arthritis
Most Recent Events
- 22 Jun 2023 Preclinical development for Rheumatoid arthritis and Psoriasis is ongoing in China (unspecified route) (Chengdu Jinrui Foundation Biotech pipeline, June 2023)
- 06 Apr 2021 Preclinical trials in Psoriasis in China (unspecified route) (Chengdu Jinrui Foundation Biotech pipeline, April 2021)
- 06 Apr 2021 Preclinical trials in Rheumatoid arthritis in China (unspecified route) (Chengdu Jinrui Foundation Biotech pipeline, April 2021)